4:04 pm Peregrine Pharma reports EPS in-line, beats on revs (PPHM) : Reports Q2 (Oct) loss of $0.05 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.05); revenues rose 21.3% year/year to $7.4 mln vs the $5.75 mln consensus.
4:04 pm Peregrine Pharma reports EPS in-line, beats on revs (PPH
回答: Q2 2014 Peregrine Pharmaceuticals Earnings Release - After Marke
由 newstudent6
于 2013-12-10 12:51:22